- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AstraZeneca PLC (AZN)
Track today's live AstraZeneca (AZN) share price, performance and key data on this page with our current London:AZN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the AstraZeneca share price on the London exchange. Use the dropdown to switch exchange for the AZN share price, head to our technical summary section, which provides analysis on AstraZeneca share price buy/sell indicators using real-time data (or discuss the AstraZeneca (AZN) stock price today with other investors in the AstraZeneca LON share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current LON:AZN share price (ISIN: GB0009895292) to enhance your trading decisions with our free investment tools and resources.
What Is the AstraZeneca PLC Share Price Today?
The AstraZeneca share price today is 12,720.0.
What Is the Stock Symbol for AstraZeneca PLC
The stock symbol (or 'ticker') for Astrazeneca Plc is "AZN."
What Stock Exchange Does AstraZeneca PLC Trade On?
Astrazeneca Plc is listed and trades on the London stock exchange.
Is AstraZeneca PLC a Good Stock to Buy?
Determining whether AstraZeneca (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current LON:AZN share price (ISIN: GB0009895292) to enhance your trading decisions with our free investment tools and resources.
What Is the AstraZeneca PLC Share Price Today?
The AstraZeneca share price today is 12,720.0.
What Is the Stock Symbol for AstraZeneca PLC
The stock symbol (or 'ticker') for Astrazeneca Plc is "AZN."
What Stock Exchange Does AstraZeneca PLC Trade On?
Astrazeneca Plc is listed and trades on the London stock exchange.
Is AstraZeneca PLC a Good Stock to Buy?
Determining whether AstraZeneca (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
12,720.0
-414.0(-3.15%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12,690.0
13,076.0
52 wk Range
10,784.0
15,730.0
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12,690.013,076.0
52 wk Range
10,784.015,730.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.82%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.82%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
AZN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
15,904.6
Upside
+25.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with low price volatility
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
17 Buy
4 Hold
2 Sell
Ratings:
23 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 15,904.6
(+25.04% Upside)
AstraZeneca PLC Earnings Call Summary for Q2/2026
- AstraZeneca Q2 2026 EPS of $2.63 beat estimates by 6%, though revenue of $15.38B missed forecasts by 0.45% amid generic competition pressures.
- Revenue grew 11% excluding Farxiga and Brilinta losses; oncology remained key growth driver with double-digit gains across major regions.
- Company reiterated 2026 guidance for mid-to-high single-digit revenue growth and low double-digit EPS growth at constant currency rates.
- Pipeline advances highlighted with positive phase III gastric cancer data; 25 phase III readouts expected over next 18 months supporting growth.
- Management reaffirmed $80B revenue target by 2030; shares rose 1.06% pre-market to $12,804 on solid execution despite transition headwinds.
Last Updated: 27/07/2026, 13:50
Read Full TranscriptEarnings
Latest Release
27/07/2026
EPS / Forecast
2.63 / 2.48
Revenue / Forecast
15.38B / 15.45B
Compare AZN to Peers and Sector
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 25.4x | 24.2x | −0.3x | |
PEG Ratio | 0.98 | 0.36 | 0.00 | |
Price/Book | 5.3x | 4.7x | 2.6x | |
Price / LTM Sales | 4.3x | 4.2x | 2.9x | |
Upside (Analyst Target) | 27.2% | 13.7% | 56.7% | |
Fair Value Upside | Unlock | 12.4% | 10.2% | Unlock |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the AstraZeneca (London: AZN) Share Price Today?
The AstraZeneca stock price today is 12,720.0 GBP.
What Stock Exchange Does AstraZeneca (AZN) Trade On?
AstraZeneca is listed and trades on the London Stock Exchange.
What Is the Ticker (Stock Symbol) for AstraZeneca?
The stock symbol (also called a 'ticker') for AstraZeneca is "AZN."
Does AstraZeneca Pay Dividends? What’s The Current AZN Dividend Yield?
Yes, AZN Pays Dividends to its Shareholders. The current AstraZeneca dividend yield is 1.82%.
What Is the Current AstraZeneca Market Capitalisation?
As of today, AstraZeneca (London: AZN) market cap is 203.71B GBP.
What Is AstraZeneca's (AZN) Earnings Per Share (TTM)?
The AstraZeneca EPS is currently 6.7 (Trailing Twelve Months).
When Is the Next AstraZeneca Earnings Date?
AstraZeneca's next earnings report will be released on 30/10/2026.
Is AZN a Buy or Sell From a Technical Analyst Perspective?
Based on today's AstraZeneca moving averages and other technical indicators, the daily buy/sell signal for AZN stock is Strong Sell.
How Many Times Has AstraZeneca Stock Split?
AstraZeneca has split 0 times. (See the AZN stock split history page for full effective split date and price information.)
How Many Employees Does AstraZeneca Have?
AstraZeneca has 96100 employees, based on their latest Companies House report.
What is the current trading status of AstraZeneca (London: AZN)?
As of 30/07/2026, AstraZeneca (AZN) is trading at a share price of 12,720.0 GBP, with a previous close of 13,134.0 GBP. The stock has fluctuated within a day range of 12,690.0 GBP to 13,076.0 GBP, while its 52-week range spans from 10,784.0 GBP to 15,730.0 GBP.
What Is AstraZeneca (AZN) Price Target According to Analysts?
The average 12-month price target for AstraZeneca is 15,904.6 GBP, with a high estimate of 20127.21165368 GBP and a low estimate of 11379.94532654 GBP. 17 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +25.04% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.